Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Reinhard Dummer

Showing results (561-570 of 745) with videos related to

Pageof 75
Sort By:
Future Oncology (London, England)|January 15, 2025
A plain language summary of the 7-year update from part 1 of the COLUMBUS study: encorafenib and binimetinib for people with BRAF V600-mutant melanomaDirk Schadendorf, Reinhard Dummer, Keith T Flaherty, et al.
European Journal of Cancer (Oxford, England : 1990)|August 23, 2019
Adverse events associated with encorafenib plus binimetinib in the COLUMBUS study: incidence, course and managementHelen J Gogas, Keith T Flaherty, Reinhard Dummer, et al.
European Journal of Cancer (Oxford, England : 1990)|May 24, 2011
Extended schedule, escalated dose temozolomide versus dacarbazine in stage IV melanoma: final results of a randomised phase III study (EORTC 18032)Poulam M Patel, Stefan Suciu, Laurent Mortier, et al.
Cell Reports|June 2, 2015
Downregulation of the Ubiquitin Ligase RNF125 Underlies Resistance of Melanoma Cells to BRAF Inhibitors via JAK1 DeregulationHyungsoo Kim, Dennie T Frederick, Mitchell P Levesque, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 25, 2022
Combination of the STING Agonist MIW815 (ADU-S100) and PD-1 Inhibitor Spartalizumab in Advanced/Metastatic Solid Tumors or Lymphomas: An Open-Label, Multicenter, Phase Ib StudyFunda Meric-Bernstam, Randy F Sweis, Stefan Kasper, et al.
The Journal of Clinical Investigation|May 1, 2025
Tebentafusp elicits on-target cutaneous immune responses driven by cytotoxic T-cells in uveal melanoma patientsRamon Staeger, Aizhan Tastanova, Adhideb Ghosh, et al.
European Journal of Cancer (Oxford, England : 1990)|May 9, 2024
COLUMBUS 7-year update: A randomized, open-label, phase III trial of encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF V600E/K-mutant melanomaDirk Schadendorf, Reinhard Dummer, Keith T Flaherty, et al.
Cancer Research Communications|May 13, 2026
Early ctDNA dynamics predict response to mosperafenib in BRAF V600-mutant metastatic colorectal cancerMartha Liliana Serrano-Serrano, Christina Godfried Sie, Oliver Bechter, et al.
Cancer Immunology Research|November 15, 2018
Peripheral Blood TCR Repertoire Profiling May Facilitate Patient Stratification for Immunotherapy against MelanomaSabrina A Hogan, Anaïs Courtier, Phil F Cheng, et al.
The Lancet. Oncology|October 27, 2018
Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trialFrank Stephen Hodi, Vanna Chiarion-Sileni, Rene Gonzalez, et al.
Pageof 75

Showing results (561-570 of 745) with videos related to

Sort By:
Pageof 75
Future Oncology (London, England)|January 15, 2025
A plain language summary of the 7-year update from part 1 of the COLUMBUS study: encorafenib and binimetinib for people with BRAF V600-mutant melanomaDirk Schadendorf, Reinhard Dummer, Keith T Flaherty, et al.
European Journal of Cancer (Oxford, England : 1990)|August 23, 2019
Adverse events associated with encorafenib plus binimetinib in the COLUMBUS study: incidence, course and managementHelen J Gogas, Keith T Flaherty, Reinhard Dummer, et al.
European Journal of Cancer (Oxford, England : 1990)|May 24, 2011
Extended schedule, escalated dose temozolomide versus dacarbazine in stage IV melanoma: final results of a randomised phase III study (EORTC 18032)Poulam M Patel, Stefan Suciu, Laurent Mortier, et al.
Cell Reports|June 2, 2015
Downregulation of the Ubiquitin Ligase RNF125 Underlies Resistance of Melanoma Cells to BRAF Inhibitors via JAK1 DeregulationHyungsoo Kim, Dennie T Frederick, Mitchell P Levesque, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 25, 2022
Combination of the STING Agonist MIW815 (ADU-S100) and PD-1 Inhibitor Spartalizumab in Advanced/Metastatic Solid Tumors or Lymphomas: An Open-Label, Multicenter, Phase Ib StudyFunda Meric-Bernstam, Randy F Sweis, Stefan Kasper, et al.
The Journal of Clinical Investigation|May 1, 2025
Tebentafusp elicits on-target cutaneous immune responses driven by cytotoxic T-cells in uveal melanoma patientsRamon Staeger, Aizhan Tastanova, Adhideb Ghosh, et al.
European Journal of Cancer (Oxford, England : 1990)|May 9, 2024
COLUMBUS 7-year update: A randomized, open-label, phase III trial of encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF V600E/K-mutant melanomaDirk Schadendorf, Reinhard Dummer, Keith T Flaherty, et al.
Cancer Research Communications|May 13, 2026
Early ctDNA dynamics predict response to mosperafenib in BRAF V600-mutant metastatic colorectal cancerMartha Liliana Serrano-Serrano, Christina Godfried Sie, Oliver Bechter, et al.
Cancer Immunology Research|November 15, 2018
Peripheral Blood TCR Repertoire Profiling May Facilitate Patient Stratification for Immunotherapy against MelanomaSabrina A Hogan, Anaïs Courtier, Phil F Cheng, et al.
The Lancet. Oncology|October 27, 2018
Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trialFrank Stephen Hodi, Vanna Chiarion-Sileni, Rene Gonzalez, et al.
Pageof 75